PIM1 kinase inhibitors induce radiosensitization in non-small cell lung cancer cells

Rhamnetin and Cirsiliol Induce Radiosensitization and Inhibition of Epithelial-Mesenchymal Transition (EMT) by miR-34a-mediated Suppression of Notch-1 Expression in Non-small Cell Lung Cancer Cell Lines

“…Previously, our group and others measured the radiosensitivity of a subset of NSCLC cells after exposure to various doses of radiation (40,42,76). In this study, NCI-H1299 and NCI-H460 cells were used as representative radioresistant and radiosensitive NSCLC cells, respectively, which is supported by a previous investigation (77).…”

“…Because several flavonoids have been reported to regulate the Notch-1 pathway in various cancer cell lines, a large number of flavonoids were prepared for screening (37,38). Based on their effect on Notch-1 expression, fewer than 10 candidates were selected and analyzed according to solubility and molecular weight along with Lipinski-like criteria (42). Ultimately, two compounds were selected for further investigation, rhamnetin and cirsiliol ( Fig.…”

“…Several studies have demonstrated that cancer cells may acquire resistance to radiation-induced apoptosis through the dynamic interplay and regulation of multiple pro-survival factors (40,42). Therefore, we next investigated the relationship of apoptosis induced by rhamnetin-or cirsiliol-radiation treatment with activation of the nuclear factor-B (NF-B) pathway in NSCLC cells.…”

AKT1S1 (AKT1 substrate 1 (proline-rich))

“…This translocation prevents the induction of pro-apoptotic genes by FOXO3, such as Bim and FasL. Treatment with PIM-1 kinase inhibitors reduces the levels of phosphorylated AKT1S1 thereby increasing the amount of nuclear FOXO3 and the radiation sensitivity of the non-small cell lung cancer cells (Kim et al, 2013;Kim et al, 2011).…”

Effects of traditional oriental medicines as anti-cytotoxic agents in radiotherapy

“…In addition, spatial-localizing techniques and radiation-fractionated therapy have improved the rate of satisfactory therapeutic outcomes by enabling the repair of radiation-induced damage and regeneration of damaged and fresh cells. Positive therapeutic outcomes may be accomplished by the development of selective radioadjuvants, including radiosensitizers and radioprotectors (4)(5)(6). In spite of the improvement in radiotherapeutic modalities, surrounding normal tissues are also affected during radiotherapy, with local tissue damage, mucositis and general weakness occurring (7)(8)(9).…”